Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population

The survival rate for patients with hematologic malignancies has been greatly improved by the development of targeted therapy, immunotherapy, and transplantation [1 –3]. Particularly, allogeneic stem cell transplantation (alloSCT) has been identified as a curative treatment modality in hematologic malignancies [2], improving the 3-year overall survival (OS) of leukemia patients to 60–70% [4,5].
Source: Leukemia Research - Category: Hematology Authors: Source Type: research